Hansa Biopharma AB (publ)
HNSBF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $2,085 | $1,402 | $2,342 | $3,718 |
| - Cash | $405 | $732 | $1,496 | $651 |
| + Debt | $1,079 | $867 | $791 | $35 |
| Enterprise Value | $2,759 | $1,537 | $1,637 | $3,102 |
| Revenue | $171 | $134 | $155 | $34 |
| % Growth | 27.8% | -13.2% | 356.1% | – |
| Gross Profit | $88 | $71 | $116 | $18 |
| % Margin | 51.2% | 52.9% | 75.1% | 54.5% |
| EBITDA | -$642 | -$706 | -$554 | -$539 |
| % Margin | -374.8% | -526.1% | -358.7% | -1,590.5% |
| Net Income | -$807 | -$832 | -$611 | -$548 |
| % Margin | -470.9% | -620.3% | -395.5% | -1,618.4% |
| EPS Diluted | -12.84 | -15.83 | -13.6 | -12.33 |
| % Growth | 18.9% | -16.4% | -10.3% | – |
| Operating Cash Flow | -$675 | -$756 | -$503 | -$481 |
| Capital Expenditures | -$0 | -$0 | -$3 | -$2 |
| Free Cash Flow | -$675 | -$756 | -$506 | -$484 |